相似文献
1
Glioma Response to IDH Inhibition: Real-World Experience.
Clin Cancer Res. 2023 Dec 1;29(23):4709-4710. doi: 10.1158/1078-0432.CCR-23-2164.
2
Ivosidenib in Isocitrate Dehydrogenase 1Mutated Advanced Glioma.
J Clin Oncol. 2020 Oct 10;38(29):3398-3406. doi: 10.1200/JCO.19.03327. Epub 2020 Jun 12.
3
Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Eur Radiol. 2020 Apr;30(4):2142-2151. doi: 10.1007/s00330-019-06548-3. Epub 2019 Dec 11.
4
Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
J Neurosurg. 2018 Feb;128(2):391-398. doi: 10.3171/2016.10.JNS161793. Epub 2017 Mar 3.
5
Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
FASEB J. 2019 Jan;33(1):557-571. doi: 10.1096/fj.201800907RR. Epub 2018 Jul 12.
6
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Oncology (Williston Park). 2013 Jun;27(6):504-14.
7
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Neuro Oncol. 2017 Jan;19(1):109-117. doi: 10.1093/neuonc/now121. Epub 2016 Jun 26.
8
Characteristics of gliomas in patients with somatic IDH mosaicism.
Acta Neuropathol Commun. 2016 Mar 31;4:31. doi: 10.1186/s40478-016-0302-y.
9
MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Radiology. 2017 Jun;283(3):799-809. doi: 10.1148/radiol.2016161422. Epub 2016 Dec 13.
10
Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison.
AJNR Am J Neuroradiol. 2021 Mar;42(3):441-447. doi: 10.3174/ajnr.A6965. Epub 2021 Jan 7.
引用本文的文献
1
Impact of SPP1 and HMOX1 Genes in Glioma: Correlations With Oncolytic Virus Infection, Adverse Prognosis and Increased Cell Proliferation.
J Cell Mol Med. 2025 Jun;29(11):e70651. doi: 10.1111/jcmm.70651.
2
Diagnostic and theranostic opportunities in Neuro-oncology.
Adv Oncol. 2024 May;4(1):111-124. doi: 10.1016/j.yao.2024.01.001. Epub 2024 Jan 29.
3
Extra-temporal pediatric low-grade gliomas and epilepsy.
Childs Nerv Syst. 2024 Oct;40(10):3309-3327. doi: 10.1007/s00381-024-06573-8. Epub 2024 Aug 27.
本文引用的文献
1
Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors.
Clin Cancer Res. 2023 Dec 1;29(23):4863-4869. doi: 10.1158/1078-0432.CCR-23-0585.
2
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4.
3
Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.
J Clin Invest. 2023 Jun 15;133(12):e168035. doi: 10.1172/JCI168035.
4
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Nat Med. 2023 Mar;29(3):615-622. doi: 10.1038/s41591-022-02141-2. Epub 2023 Feb 23.
5
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Neuro Oncol. 2023 Jan 5;25(1):4-25. doi: 10.1093/neuonc/noac207.
6
In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of -Mutant Diffuse Gliomas: The Prospective Study.
Neurology. 2023 Jan 3;100(1):e94-e106. doi: 10.1212/WNL.0000000000201137. Epub 2022 Sep 30.
7
Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas.
Neurooncol Adv. 2022 Aug 4;4(1):vdac124. doi: 10.1093/noajnl/vdac124. eCollection 2022 Jan-Dec.
8
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
J Neurooncol. 2019 Oct;145(1):115-123. doi: 10.1007/s11060-019-03277-x. Epub 2019 Sep 25.
9
Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study.
J Neurol. 2018 Jun;265(6):1432-1442. doi: 10.1007/s00415-018-8857-0. Epub 2018 Apr 23.
10
Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
Neuro Oncol. 2018 Aug 2;20(9):1197-1206. doi: 10.1093/neuonc/noy051.
Zotero 插件